XSHE
002349
Market cap1.08bUSD
Oct 09, Last price
9.24CNY
1D
5.96%
1Q
40.64%
Jan 2017
-8.29%
IPO
173.91%
Name
Jinghua Pharmaceutical Group Co Ltd
Chart & performance
P/E
35.02
P/S
5.31
EPS
0.26
Div yield, %
0.90%
Shrs. gr., 5y
—
Rev. gr., 5y
1.28%
Revenues
1.45b
+3.19%
Net income
219m
+3.12%
CFO
347m
+11.47%
Dividend
May 29, 20260.09 CNY/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Established in 1957 and headquartered in Nantong, China, Jinghua Pharmaceutical Group Co., Ltd. is a Chinese enterprise dedicated to the complete process of active pharmaceutical ingredients (APIs) and pharmaceutical intermediates, encompassing their research, development, manufacturing, and distribution. Its essential API offerings include a variety of compounds such as Phenylbutazone, Primidone, Phenobarbital, Fluorouracil, Propylthiouracil, Piroxicam, and Flucytosine. The company previously operated under the name Nantong Jinghua Pharmaceutical Co., Ltd.
Key people
Hongyu Yin
Chairman of the Board
Chunlin Zhu
Chairman of the Board · since 2017
Yunzhong Zhou
General Manager, Director · since 2017
Jian Cheng
Deputy General Manager · since 2021
Yuxiang Wu
Finance Director, Executive Deputy General Manager, Director · since 2021
Qianyong Zhu
Deputy General Manager
Secretary of the Board · since 2021
Jian Lu
Director · since 2025
Jianqiao Zhang
Director
Qiaogen Feng
Independent Director
Jing Liu
Independent Director · since 2024
Ling Ma
Independent Director · since 2021
Xu Wang
Independent Director · since 2021
Xiaomei Zhang
Independent Director · since 2024
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2023‑00 | 2022‑12 | 2022‑00 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||||
Revenues | ||||||||||||
Cost of revenue | ||||||||||||
Unusual Expense (Income) | ||||||||||||
NOPBT | ||||||||||||
NOPBT Margin | ||||||||||||
Operating Taxes | ||||||||||||
Tax Rate | ||||||||||||
NOPAT | ||||||||||||
Net income | ||||||||||||
Dividends | ||||||||||||
Dividend yield | ||||||||||||
Proceeds from repurchase of equity | ||||||||||||
BB yield | ||||||||||||
| Debt | ||||||||||||
Debt current | ||||||||||||
Long-term debt | ||||||||||||
Deferred revenue | ||||||||||||
Other long-term liabilities | ||||||||||||
Net debt | ||||||||||||
| Cash flow | ||||||||||||
Cash from operating activities | ||||||||||||
CAPEX | ||||||||||||
Cash from investing activities | ||||||||||||
Cash from financing activities | ||||||||||||
FCF | ||||||||||||
| Balance | ||||||||||||
Cash | ||||||||||||
Long term investments | ||||||||||||
Excess cash | ||||||||||||
Stockholders' equity | ||||||||||||
Invested Capital | ||||||||||||
ROIC | ||||||||||||
ROCE | ||||||||||||
| EV | ||||||||||||
Common stock shares outstanding | ||||||||||||
Price | ||||||||||||
Market cap | ||||||||||||
EV | ||||||||||||
EBITDA | ||||||||||||
EV/EBITDA | ||||||||||||
Interest | ||||||||||||
Interest/NOPBT | ||||||||||||